When Is Surgery Alone No Longer Enough?
In this case-based discussion, a multidisciplinary panel examines recurrent high-risk CSCC, including the distinction between local recurrence and in-transit disease, considerations for additional surgery and radiation, and the role of adjuvant immunotherapy following surgery and radiation.
This is Part 1 of 4:
Part 1: When Is Surgery Alone No Longer Enough?
Part 2: How Do You Determine the Best Treatment Strategy?
Part 3: How Can the Multidisciplinary Team Optimize Patient Care?
Part 4: Practical Strategies for Multidisciplinary CSCC Care
Dr Stan Tolkachjov: Let's start with our first case today. This will be a discussion. And then, in cutaneous SCC care, when is surgery alone no longer enough?
Dr Mehran Yusuf: So, for the first case today, we're going to be talking about an 80-year-old gentleman, a little bit about his past medical history, no known immune suppression. He’s from the greater Alabama region, so unfortunately a high-UV-exposure region, so, we have a lot of people who are out in the sun. And subsequently has had a history of a lot of non-melanoma skin cancers, basal cells, cutaneous squames, including one that was excised with Mohs overlying the right malar cheek. After, it was a clear margin but had some higher-risk factors. It was greater than two centimeters, and it was actually going deep to the subcutaneous fat. Afterwards, didn't get adjuvant therapy, and had a period of about a year or so when he was doing well before they palpated a little bit of a nodule kind of in the right malar cheek, maybe three centimeters from the excision site there. Went through the normal workup process, so had staging imaging with the CT of the chest as well as the neck. Ended up getting a biopsy of that lesion, which showed squamous cell carcinoma. Ended up sending it for NGS, so it showed UV signature and was TMB high as well. That whole workup process, including a referral to a specialty center, took several months. And this thing, thankfully, was relatively stable, didn't change in size as much, because we always worry about in-transit or satellite disease having maybe a more aggressive pattern of spreading, where surgical resection may not be as favored.
So, this case was discussed at our multidisciplinary tumor board. This patient elected to undergo surgery and had a wide local excision as well as a neck dissection, I think a superficial parotidectomy. Microscopically positive margin was noted. And so other characteristics or risk factors is poorly differentiated, the recurrence was greater than two centimeters, considered high risk for recurrence. Then ended up seeing our team for adjuvant radiation. And with the new data today and looking at the high-risk factors with an in-transit or satellite lesion, he was also considered adjuvant immune therapy. And really curious to get your all's perspectives as well, because unfortunately, I think this is a situation that's not super common, but we're all at high-volume referral centers. So, we do see this fairly often, and there are a lot of different ways to manage it.
Dr Stan Tolkachjov: Actually, you're right. It's a pretty typical case when you see a high volume. And we do know that cutaneous SCCs, unlike some of the other malignancies, can metastasize quickly to the nodes. And so, I think this brings up a really good patient. After the Mohs surgery, he then had a recurrence, and it was an in-transit disease, not to the lymph nodes, though, to your knowledge at the time, right?
Dr Mehran Yusuf: Correct.
Dr Stan Tolkachjov: Okay, okay. And so, I would say that, what would be, what was your next step? What did we, what are you looking at as far as the extent of the disease? What are the surgical options? What other therapies can we do?
Dr Mehran Yusuf: Yeah, absolutely. And, you know, just characterizing some of the things that we thought up for this patient. Looking at CSCC, these satellite lesions tend to be a pretty aggressive risk feature. Looking at some of the data, they are pretty rare, but the Brigham and Women's Hospital and I think Cleveland Clinic did a joint analysis, and it seems to be similar to having node-positive disease. So, we always think about, should we do something different from our normal management?
Dr Stan Tolkachjov: As far as the surgical option, is there a surgical option for this patient?
Dr Kevin Emerick: So, I think that you mentioned some really important things that I think language here becomes so important in how we think about these patients and helps really guide how we think about the different modalities of treatment. Because this sounds like a situation that we routinely encounter, where is this actually just a local recurrence or is it an in-transit metastasis? I think that's really important as we think about the role of surgery in this moment. Because if it is a local recurrence, there is certainly a reasonable chance that with more surgery, we could provide a benefit to that patient. Whereas if this is truly an in-transit metastasis, there's a pretty high chance that there is other microscopic occult disease that we can't detect. And therefore, surgery has less of a benefit. It may still have a role, but that's when we start to think about “Boy, does radiation with a broader field or a systemic therapy offer more of a benefit?” So that initial presentation, and understanding that, is really important in terms of how we think about, or at least how I think about, the role of surgery.
Dr Stan Tolkachjov: I agree. From a dermatology perspective, a lot of times we'll see a path report, and it'll say there's no epidermal connection. And that's when we know it's more likely to be an in-transit met, rather than a local recurrence, at the site of a scar or even a reactive keratoacanthoma squamous cell. So, it's really good to know, to identify which one is it? Is it the in-transit met? Which is, of course, you mentioned, both of y'all, the high-risk factor, versus the local recurrence. And I think that's something we first have to know. And then, Dr Chandra, you mentioned, or we want to talk to you about immunotherapy and the role of immunotherapy in this particular patient.
Dr Sunandana Chandra: Yeah, I think, for this particular person who had recurrent disease, likely an in-transit metastasis, which puts them at higher risk, I think we can think of these various options to actually lead to quite meaningful outcomes. So, for example, Kevin, you mentioned that perhaps surgery for an in-transit metastasis may not provide the kind of control that we want. Which may be true. However, if we do surgery followed perhaps by adjuvant radiation and then followed perhaps by adjuvant immunotherapy, perhaps we actually can control the disease in this particular person.
When we have a person in front of us with these high-risk features, they've been resected, I think my role as a medical oncologist is to understand: is there something that I can recommend to them, such as a year of adjuvant therapy, that could truly impact their risk of recurrence? Just because I can, doesn't necessarily always mean that I should. So, we have to take the person in front of us, their tumor-associated factors, the person, their clinical factors and characteristics. And then, of course, keep in mind what their goals are for trying to manage the disease.
Dr Stan Tolkachjov: And I know in the beginning of the case, obviously, T2b was the stage, by Brigham and Women's criteria. We definitely want to stage this patient still, right? And so, when you look at what you're going to do next after you first find out the patient has had in-transit mets. So obviously, before we consider surgery or immunotherapy, we should stage the patient, right?
So, when you look at this case, what imaging techniques would you do? Would you do something else to see? Would you do ctDNA, for example? Circulating tumor DNA. Would you do some sort of genetic expression profile? What imaging would you do and what things would you do to stage this patient, at his current stage?
Dr Mehran Yusuf: Absolutely. I think for anybody where we expect or believe that they have a satellite or in-transit lesion, we want to, at a minimum, localize the area where it is, and then the areas where you may have regional or non-regional metastases. So, for him, we've got a CT of the neck and the chest, and I think after a PET CT, as well, just to make sure there weren't any other areas that were maybe FDG avid that weren't appreciated as being malignant by normal CT criteria.
Dr Stan Tolkachjov: And now we've discussed that possibly there's a surgical option, especially if it's local recurrence rather than in-transit recurrence. We've talked about staging and imaging, and I love the fact that you're doing the CT, but also to be able to offer PET scan for some of these patients, which would be great. So now we've said, “okay, this patient is in-transit met. They probably can be resected, maybe not.” And so, I'm going to go back to our medical oncology colleague here. Su, do you think in this case, would you have them first get radiation and then get immunotherapy after that, knowing so far it's a localized disease with a one-in-transit met? And how would you follow that patient?
Dr Sunandana Chandra: Yeah, that's a great question. I mean, I think the first thing I would do would be to call Kevin and Yusuf, so we could have a truly multidisciplinary discussion. And hopefully that call will happen before any of us do anything, right? Because I think for this particular person, we actually have a couple of different options. We could think about neoadjuvant immunotherapy from the medical oncology perspective, followed by surgery, and then path review, etc. We could also think about surgery first, followed by adjuvant therapy, and then perhaps followed by more adjuvant immunotherapy. So, I think for this particular case, we have a couple of things to consider. And I think that's where it's so important for me to pick up the phone and call my colleagues to figure out what the best path forward is. There are risks associated with immunotherapy, and so, I don't take that decision lightly, and I really want to converse with my colleagues to figure out, for this person in front of us, what is the best course of action?
Dr Kevin Emerick: And I think it's important, Stan, as well to think about, you asked that very specific question, is adjuvant immunotherapy appropriate here, or should we be thinking about it? We have to remember that the current FDA approval and guidelines is to be done after radiation therapy. And so, in many ways, before we even ask that question, we have to say, is this person appropriate for radiation therapy too? I think, as we might get excited about the potential for immunotherapy as an immediate postoperative therapy. We're not quite there yet. And I think that's just an important thing for us to keep in mind as we evaluate these folks.
Dr Stan Tolkachjov: I think that's a great point. And to touch base on that again, if you did do surgery and you achieved clear margins, would immunotherapy work as well? Because at that point, right, you don't have, technically, tumor left in the patient. So, would immunotherapy work as well?
Dr Sunandana Chandra: Yeah, that's a great question. I mean, we certainly have a lot of data in non-cutaneous squamous cell cancer, specifically in melanoma. But in CSCC, we just don't have that data. So, the question is: is there a role for adjuvant immunotherapy without adjuvant radiation, given the current data that we have? And I think right now, I would be a little bit hesitant to treat outside the box just because the data is fairly new. So, I would like to try to follow the C-POST trial data to the best of my ability.
Dr Mehran Yusuf: And to your point, Stan, it's so hard because unlike in the neoadjuvant setting where you have a pathologic biomarker on if this person's tumor is going to be sensitive to immune therapy, it's so hard in the adjuvant setting. Whether it's PD-L1 or TMB, we've got things that have some signal, but we don't have a perfect biomarker to be able to predict which patients after surgery are going to benefit from the immune therapy. Hopefully we'll get some new data that'll present that as an option moving forward. But just like Su mentioned, I think our team's had a tough time deviating from how these studies have been set up to date. Every patient's different. So, I think that multi-D discussion could incorporate it, but yeah, that's where we are too.
Dr Stan Tolkachjov: Yeah. And I think because of that, you'll be the first person really to start. Because if we're going to go to immunotherapy after radiation, we want to have that discussion with a patient about the pluses and minuses of radiation. And then it's going to be up to the patient to either accept that or refuse it, right?
And so, I love how we're kind of thinking about the different options for this current patient, what the research will be eventually, and how we can broaden those options. And so, I think, as we close this particular patient out and think through it, from what I hear is we stage them, we have a multidisciplinary discussion to see what's best for the patient. We, of course, speak to the patient and get what he or she wants to do. And then, we then go with possible radiation, maybe surgery prior to radiation, and then consider immunotherapy. And then we may monitor those patients clinically, radiographically, or maybe even the ctDNA has a place in that.
And so, the current patient, of course, did get radiation therapy, correct?
Dr Mehran Yusuf: Yeah. So, in this case, they had that initial surgery with the microscopically involved or positive margin, then had radiation after. But to your point, one of the important things that we wanted to broach up front with them meeting C-POST high-risk, is having, what we believe is a satellite or in-transit lesion. We did mention, because oftentimes patients will ask, “I really don't want this to come back. What else can I do in addition to the radiation?” And I think it's really important to bring that up front. People are pretty overwhelmed at time of diagnosis for recurrence. And so, you definitely don't want to stress somebody out. But, we see them at least once a week for under-treatment visits. So, towards the end of radiation or mid, I will bring up like, “Hey, we do have excellent colleagues in medical oncology who can talk to you about this if this is an option.” And it usually at least puts a nugget in their head, where they're not then just surprised at the end like, "I thought it was done. What do you mean I have to see somebody else?”
Dr Stan Tolkachjov: Yeah, that's a really good point. So, when we... After this treatment plan, who really owns the follow-up? You know, of course, I'm a dermatologist, and we will see these patients for skin checks. Of course, palpate nodes… But who owns? Also, the imaging, for example, who will then see their potential side effects from radiation and potentially from immunotherapy, or even some of their surgical side effects. So, who owns that patient?
Dr Mehran Yusuf: I guess, you all, please go ahead.
Dr Stan Tolkachjov: Go ahead, please.
Dr Kevin Emerick: Well, I was going to say, I think the person who should take care of this person is a disease expert, and that doesn't have to be your background in dermatology or medical oncology, radiation, etc, but somebody who's truly a disease expert. I will say, I think that is a broad way to think about it. Another way to think about it is what is the most likely way for this to come back, and who's going to be the best person to detect that? And if that is, this person is most likely to have a lung and a liver met, for example, maybe that is someone who's really focused on systemic therapies and systemic imaging. But if that therapy is, or that recurrence is likely to be a local or regional, maybe the surgeon is more comfortable with that. I think the radiation team can fall into that category in a lot of ways, but I think that somebody who really understands the whole spectrum of this disease, regardless of their residency training or board certification, is the best person to keep an eye on this.
Dr Stan Tolkachjov: And remember, we also have, those of us that work with, for example, advanced practice providers and nurse practitioners, physician associates. And so, they may be seen doing the skin checks on these patients and seeing them and be the first ones to actually recognize potential metastasis, if they do the lymph node palpation. So, I think what we started with the earlier saying we should get a multidisciplinary team. Whoever will see that patient also for skin checks, whoever that expert is, I think would be great to be involved as well. And I love your point about a cancer, or that oncology expert, who owns that disease. I think they should maybe quarterback or guide the follow-up and maybe all of us be involved with our group.
©️ 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of The Dermatologist, HMP Global, or its employees and affiliates.


